Glycinorm Total 60 Tablet SR is a combination oral antidiabetic medication containing Gliclazide 60 mg, Pioglitazone 15 mg, and Metformin 500 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Pioglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving glucose uptake in adipose tissue and muscle. Metformin, a biguanide, decreases hepatic gluconeogenesis and enhances peripheral glucose utilization, contributing to improved insulin sensitivity. The combination targets multiple pathophysiological defects of type 2 diabetes, providing complementary mechanisms to achieve better glycemic control. Glycinorm Total 60 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy with these agents. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, heart failure, or risk factors for lactic acidosis. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. This combination therapy should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring.